Search

everythinglearnresearchcommunity

for

Search:↓

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

The FDA approved a new Pfizer drug for hair loss in teens.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Drug repurposing speeds up drug development, saves money, and has led to about a third of new drug approvals.

Nanotechnology shows promise for treating hair loss but faces safety and approval challenges.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Thermoresponsive nanogels show promise for delivering medicine through the skin but need more safety testing and regulatory approval before clinical use.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Drug repurposing can speed up and reduce costs in drug discovery, especially for cancer treatment.

Nanocomposite patches improve drug delivery through the skin, offering controlled release and fewer side effects.

The C3H/HeJ mouse model is useful for studying and testing treatments for alopecia areata.

The conclusion is that off-label drug use can lead to important medical discoveries and improve patient care.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

High-content screening is useful for finding new treatments for rare diseases and has led to FDA-approved drugs.

Marine biomaterials show promise for drug delivery and wound healing.

ODAC members faced intense pressure but prioritized scientific evidence in drug approval decisions.

Pediatric systemic lupus erythematosus is a severe autoimmune disease in children requiring early diagnosis and comprehensive management.

Microneedles are becoming essential tools in medicine for sensing, drug delivery, and communication.

Hydrogels show promise in preventing and treating skin damage from radiation therapy.

We need to study how dissolving microneedles behave in the body to use them for medicine.

Nanotechnology could improve hair regrowth but faces challenges like complexity and safety concerns.

Microneedles could revolutionize pediatric medicine by offering painless drug delivery, but more development is needed.

The document concludes that doctors should carefully consider off-label drug use in dermatology and always inform patients, while more research is needed on the safety and effectiveness of such practices.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

The US and EU lead in cell and gene therapy regulations with more approvals and clinical trials, while India is in early stages with fewer approvals and expedited processes.

The committee decided not to approve the drug due to low effectiveness and high risks.

A woman with Parkinson's disease experienced hair loss from the Parkinson's medication pramipexole, which improved after stopping the drug.

Haloperidol effectively treated hemiballismus, but spontaneous improvement wasn't ruled out; rapid weight loss can cause hair loss with good regrowth chances.